Mind Medicine (MindMed) Inc. (MNMD) NASDAQ
20.69
+0.09(+0.44%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
20.69
+0.09(+0.44%)
Currency In USD
Address
1055 West Hastings Street
Vancouver, BC V6E 2E9
Canada
Phone
650 208 2454
Website
Sector
Healthcare
Industry
Biotechnology
Employees
74
First IPO Date
November 15, 2016
| Name | Title | Pay | Year Born |
| Robert Barrow | Chief Executive Officer & Director | 997,010 | 1989 |
| Scott Freeman | Co-Founder & Clinical Advisor | 312,005 | 1957 |
| Brandi L. Roberts | Chief Financial Officer | 608,624 | 1974 |
| Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | 638,607 | 1971 |
| Daniel Rollings Karlin | Chief Medical Officer | 703,319 | 1980 |
| Gregg Pratt | Chief Regulatory & Quality Assurance Officer | 0 | N/A |
| Leonard Latchman | Co-Founder | 0 | N/A |
| Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | 0 | N/A |
| Beth Calitri | Vice President of Corporate Communications | 0 | N/A |
| Gitanjali Jain | VP & Head of Investor Relations | 0 | N/A |
| Stephanie Fagan | Chief Corporate Affairs Officer | 0 | N/A |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.